Nanoparticles for drug delivery: the need for precision in reporting particle size parameters.

By M. Gaumet, A. Vargas, R. Gurny, F. Delie. European journal of pharmaceutics and biopharmaceutics, 2008

1,047 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Nanocarrier Drug Delivery Systems: Characterization, Limitations, Future Perspectives and Implementation of Artificial Intelligence (2022, background): “DLS is generally considered inappropriate for measurements within biological media [25].”
Challenges in Development of Nanoparticle-Based Therapeutics (2012, background): “Previous reports have shown that nanoparticles of 150–300 nm locate mainly in the liver and spleen (25), and colloids of sizes 200 to 400 nm undergo rapid hepatic clearance (26).”
Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination. (2016, background): “Circulating nanoparticles smaller than the diameter of liver sinusoidal fenestrations (up to 150–200 nm) can extravasate into the space of Disse and interact directly with hepatocytes [9,25,90,91].”
PLGA-based nanoparticles: an overview of biomedical applications. (2012, methodology): “This technique is based on the dispersion of the light caused by the Brownian motion of the particles [18].”